Overview

A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary angiography/percutaneous coronary intervention (PCI).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Daiichi Sankyo Co., Ltd.
Treatments:
Prasugrel Hydrochloride